moneyheap
IQV · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is IQVIA Holdings Inc. (IQV) stock moving?
IQVIA reported third-quarter 2026 results on Oct 27 (8-K filing), but the excerpt provided does not include the reported figures. The stock traded at its high of the window on Oct 27 (intraday high $284.50) on the heaviest volume in the data (2.10M shares), then closed at $271.55. From Oct 28 to Oct 29, six brokers raised price targets: Redburn to $299, TD Cowen to $307, Evercore to $310, Baird to $328, JP Morgan to $325 and Truist to $346. Those targets average about $319, roughly 16% above the Nov 10 close of $275.15. The shares then slid to a low of $257.35 on Nov 2 and closed at $258.44, before recovering to $278.84 on Nov 9 and $275.15 on Nov 10. Volume was above 1.3M shares on most sessions in the recovery, with no single day near the Oct 27 peak, which suggests no fresh buying or selling wave. The stock now trades in the high-270s to low-280s area that marked the late-October range, with the Nov 2 low near $257 as the nearest floor. A GENFIT-related estimate published Nov 5 (U.S. peak sales above $1.5B by 2033) is a minor, long-dated item. The main positive is the consistent analyst support; the main risks are the lack of reported Q3 figures in the available data and the sharp Nov 2 drop, which shows the stock is sensitive to sentiment.
News behind the analysis
- TD Cowen Maintains Buy on IQVIA Holdings, Raises Price Target to $307TD Cowen kept its Buy rating on IQVIA and raised its price target to $307.
- JP Morgan Maintains Overweight on IQVIA Holdings, Raises Price Target to $325JP Morgan kept its Overweight rating on IQVIA and raised its price target to $325.
- Rothschild & Co Redburn Adjusts Price Target on IQVIA Holdings to $299 From $287Rothschild & Co Redburn raised its IQVIA price target from $287 to $299.
- Truist Securities Maintains Buy on IQVIA Holdings, Raises Price Target to $346Truist kept its Buy rating on IQVIA and raised its price target to $346, the highest in this set of notes.
- Evercore ISI Group Maintains Outperform on IQVIA Holdings, Raises Price Target to $310Evercore ISI kept its Outperform rating on IQVIA and raised its price target to $310.
- Baird Maintains Outperform on IQVIA Holdings, Raises Price Target to $328Baird kept its Outperform rating on IQVIA and raised its price target to $328.
- Truist Adjusts Price Target on IQVIA Holdings to $346 From $329, Maintains Buy RatingTruist raised its IQVIA price target from $329 to $346 and kept its Buy rating.
- IQVIA Estimates Significant U.S. Market Potential for GENFIT TechnologyIQVIA projected that U.S. peak annual sales for products using GENFIT's technology could exceed $1.5 billion by 2033.
About IQVIA Holdings Inc.
IQVIA is one of the world's largest contract research organizations (CROs). Drug and biotech companies hire it to run clinical trials, and it also sells healthcare data, analytics and software. What sets it apart is that it pairs large-scale trial management with a huge collection of healthcare data, and it is increasingly adding AI tools, with about 415 AI agents deployed as of late 2026.
How it makes money
Most of its revenue, roughly 60%, comes from Research & Development Solutions. In this segment, pharma and biotech clients pay IQVIA to run clinical trials under multi-year contracts. As of September 2026, the contract backlog was about $33 billion. Technology & Analytics Solutions brings in roughly 35–40%. This segment sells healthcare data, analytics, consulting and software to life-sciences companies. A small Contract Sales & Medical Solutions unit provides outsourced sales staff. The company expects about $17.4 billion in revenue for 2026.
What usually moves IQV
- Biotech funding and pharma R&D budgets
- Clinical trial bookings and backlog growth
- Drug pricing and other healthcare policy
- AI adoption and data/technology demand
- Acquisitions, debt levels and share buybacks